vs

Side-by-side financial comparison of DORCHESTER MINERALS, L.P. (DMLP) and MEDIFAST INC (MED). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $41.9M, roughly 1.8× DORCHESTER MINERALS, L.P.). On growth, DORCHESTER MINERALS, L.P. posted the faster year-over-year revenue change (5.4% vs -36.9%). Over the past eight quarters, DORCHESTER MINERALS, L.P.'s revenue compounded faster (16.2% CAGR vs -34.4%).

Dorchester Minerals, L.P. is a publicly traded master limited partnership based in the United States. It acquires, owns, and manages a diversified portfolio of royalty interests, net profit interests, and mineral properties associated with oil, natural gas, and natural gas liquids production across key onshore U.S. energy basins, delivering stable cash flow returns to its unitholders.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

DMLP vs MED — Head-to-Head

Bigger by revenue
MED
MED
1.8× larger
MED
$75.1M
$41.9M
DMLP
Growing faster (revenue YoY)
DMLP
DMLP
+42.3% gap
DMLP
5.4%
-36.9%
MED
Faster 2-yr revenue CAGR
DMLP
DMLP
Annualised
DMLP
16.2%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DMLP
DMLP
MED
MED
Revenue
$41.9M
$75.1M
Net Profit
$16.2M
Gross Margin
69.4%
Operating Margin
-10.4%
Net Margin
38.7%
Revenue YoY
5.4%
-36.9%
Net Profit YoY
13.7%
EPS (diluted)
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DMLP
DMLP
MED
MED
Q4 25
$41.9M
$75.1M
Q3 25
$35.4M
$89.4M
Q2 25
$32.4M
$105.6M
Q1 25
$43.2M
$115.7M
Q4 24
$39.7M
$119.0M
Q3 24
$53.5M
$140.2M
Q2 24
$37.4M
$168.6M
Q1 24
$31.0M
$174.7M
Net Profit
DMLP
DMLP
MED
MED
Q4 25
$16.2M
Q3 25
$11.2M
$-2.3M
Q2 25
$12.3M
$2.5M
Q1 25
$17.6M
$-772.0K
Q4 24
$14.2M
Q3 24
$36.4M
$1.1M
Q2 24
$23.6M
$-8.2M
Q1 24
$18.2M
$8.3M
Gross Margin
DMLP
DMLP
MED
MED
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
DMLP
DMLP
MED
MED
Q4 25
-10.4%
Q3 25
-4.6%
Q2 25
-1.0%
Q1 25
-1.1%
Q4 24
0.6%
Q3 24
1.5%
Q2 24
-4.7%
Q1 24
4.5%
Net Margin
DMLP
DMLP
MED
MED
Q4 25
38.7%
Q3 25
31.5%
-2.5%
Q2 25
38.1%
2.3%
Q1 25
40.9%
-0.7%
Q4 24
35.9%
Q3 24
68.1%
0.8%
Q2 24
63.2%
-4.8%
Q1 24
58.6%
4.8%
EPS (diluted)
DMLP
DMLP
MED
MED
Q4 25
$-1.64
Q3 25
$-0.21
Q2 25
$0.22
Q1 25
$-0.07
Q4 24
$0.08
Q3 24
$0.10
Q2 24
$-0.75
Q1 24
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DMLP
DMLP
MED
MED
Cash + ST InvestmentsLiquidity on hand
$41.9M
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
Total Assets
$309.6M
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DMLP
DMLP
MED
MED
Q4 25
$41.9M
$167.3M
Q3 25
$41.6M
$173.5M
Q2 25
$36.5M
$162.7M
Q1 25
$41.5M
$164.6M
Q4 24
$42.5M
$162.3M
Q3 24
$56.5M
$170.0M
Q2 24
$35.2M
$163.5M
Q1 24
$37.7M
$156.4M
Stockholders' Equity
DMLP
DMLP
MED
MED
Q4 25
$198.9M
Q3 25
$214.7M
Q2 25
$216.0M
Q1 25
$211.0M
Q4 24
$210.1M
Q3 24
$207.3M
Q2 24
$205.3M
Q1 24
$211.0M
Total Assets
DMLP
DMLP
MED
MED
Q4 25
$309.6M
$248.0M
Q3 25
$330.4M
$268.2M
Q2 25
$325.6M
$269.3M
Q1 25
$349.0M
$280.0M
Q4 24
$366.8M
$284.2M
Q3 24
$403.4M
$291.2M
Q2 24
$176.0M
$293.5M
Q1 24
$184.8M
$302.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DMLP
DMLP
MED
MED
Operating Cash FlowLast quarter
$34.3M
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
2.12×
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DMLP
DMLP
MED
MED
Q4 25
$34.3M
$-5.3M
Q3 25
$34.3M
$12.1M
Q2 25
$30.5M
$-3.4M
Q1 25
$33.4M
$3.4M
Q4 24
$31.5M
$-4.9M
Q3 24
$43.7M
$9.1M
Q2 24
$29.4M
$13.1M
Q1 24
$28.0M
$7.3M
Free Cash Flow
DMLP
DMLP
MED
MED
Q4 25
$-6.6M
Q3 25
$10.8M
Q2 25
$-4.8M
Q1 25
$1.9M
Q4 24
$-7.2M
Q3 24
$7.7M
Q2 24
$11.1M
Q1 24
$5.4M
FCF Margin
DMLP
DMLP
MED
MED
Q4 25
-8.8%
Q3 25
12.0%
Q2 25
-4.5%
Q1 25
1.6%
Q4 24
-6.1%
Q3 24
5.5%
Q2 24
6.6%
Q1 24
3.1%
Capex Intensity
DMLP
DMLP
MED
MED
Q4 25
1.8%
Q3 25
1.5%
Q2 25
1.3%
Q1 25
1.3%
Q4 24
1.9%
Q3 24
1.0%
Q2 24
1.1%
Q1 24
1.1%
Cash Conversion
DMLP
DMLP
MED
MED
Q4 25
2.12×
Q3 25
3.07×
Q2 25
2.47×
-1.36×
Q1 25
1.89×
Q4 24
2.21×
Q3 24
1.20×
8.04×
Q2 24
1.25×
Q1 24
1.54×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DMLP
DMLP

Royalties$34.0M81%
Other$7.8M19%

MED
MED

Segment breakdown not available.

Related Comparisons